Peter Jüni to Everolimus
This is a "connection" page, showing publications Peter Jüni has written about Everolimus.
Connection Strength
0.725
-
Biodegradable-polymer stents versus durable-polymer stents - Authors' reply. Lancet. 2019 05 11; 393(10184):1933.
Score: 0.165
-
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018 09 01; 392(10149):737-746.
Score: 0.158
-
Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention. 2018 01 20; 13(13):1565-1573.
Score: 0.151
-
A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. PLoS One. 2017; 12(8):e0182632.
Score: 0.146
-
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention. 2018 Aug 20; 14(6):692-699.
Score: 0.039
-
Bioresorbable scaffolds: in search of event-free dissolution. Lancet. 2017 08 19; 390(10096):720-722.
Score: 0.036
-
Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. EuroIntervention. 2014 Jan 22; 9(9):1076-84.
Score: 0.029